PDF(Pubmed)
Abstract：
Glucagon-like peptide-1 receptor agonist liraglutide may have beneficial effects on atherosclerosis development in impaired glucose tolerance (IGT). To the best of our knowledge, however, little conclusive evidence from clinical trials has been presented. The present study aimed to investigate the effect of liraglutide on atherosclerosis progression in patients with IGT. The present study was a double-blind, randomized controlled clinical trial. A total of 39 of patients aged 20-75 years who were overweight or obese (BMI, 27-40 kg/m2) and presented IGT were randomized to receive liraglutide (n=17) or lifestyle interventions (n=22) for 6 months. Serum glucose and insulin (INS) levels, lipid profile, inflammatory biomarkers and carotid intima-media thickness (CIMT) were assessed at the start and end of each treatment. Side effects were also recorded. Liraglutide treatment was found to significantly improve glycaemia, including glycosylated hemoglobin, fasting and postprandial glucose as well as INS levels (all P<0.001). Liraglutide also significantly decreased serum total cholesterol and low-density lipoprotein levels (all P<0.001). Furthermore, serum levels of inflammatory biomarkers, as well as CIMT, were decreased following liraglutide treatment compared with those in the lifestyle intervention group (all P<0.001). Kaplan-Meier analysis showed that the risk of vasculopathy in the liraglutide group was lower than that in the lifestyle intervention group (log-rank test; P=0.041). The monitoring of drug-associated side effects indicated that the dose of liraglutide (0.6 to 1.2 mg/QD via subcutaneous injection) was safe and well-tolerated. The present study suggested that liraglutide may slow atherosclerosis development and improve inflammatory status as well as intimal function in patients with IGT with few side effects. The trial was registered through the Chinese Clinical Trial Registry (ChiCTR; trial registration no. ChiCTR2200063693; retrospectively registered) on Sep 14, 2022.
摘要：
胰高血糖素样肽-1受体激动剂利拉鲁肽可能对糖耐量受损（IGT）的动脉粥样硬化发展具有有益作用。据我们所知,然而,几乎没有来自临床试验的确凿证据。本研究旨在探讨利拉鲁肽对IGT患者动脉粥样硬化进展的影响。目前的研究是双盲的,随机对照临床试验。共有39名年龄在20-75岁之间的患者超重或肥胖（BMI，27-40kg/m2），并提出的IGT随机接受利拉鲁肽（n=17）或生活方式干预（n=22）6个月。血清葡萄糖和胰岛素（INS）水平，血脂谱,在每次治疗开始和结束时评估炎症生物标志物和颈动脉内膜中层厚度(CIMT).还记录了副作用。发现利拉鲁肽治疗显着改善血糖，包括糖化血红蛋白,空腹和餐后血糖以及INS水平（均P<0.001）。利拉鲁肽还显著降低了血清总胆固醇和低密度脂蛋白水平(均P<0.001)。此外，血清炎症生物标志物水平，以及CIMT，与生活方式干预组相比，利拉鲁肽治疗后下降（均P<0.001）。Kaplan-Meier分析显示,利拉鲁肽组血管病变风险低于生活方式干预组(log-rank检验;P=0.041)。药物相关副作用的监测表明，利拉鲁肽的剂量（通过皮下注射0.6至1.2mg/QD）是安全且耐受性良好的。本研究表明，利拉鲁肽可以减缓动脉粥样硬化的发展，改善IGT患者的炎症状态和内膜功能，副作用少。该试验通过中国临床试验注册中心(ChiCTR；试验登记号。ChiCTR2200063693；回顾性注册），2022年9月14日。
